# Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

> **NCT00912418** · NA · COMPLETED · sponsor: **Craig L Slingluff, Jr** · enrollment: 14 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** autologous tumor cells plus GM-CSF-in Adjuvant

## Key facts

- **NCT ID:** NCT00912418
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05-01
- **Primary completion:** 2002-09-17
- **Final completion:** 2002-10-09
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00912418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00912418, "Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00912418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*